Corvus Pharmaceuticals, Inc.
Biopharma, Biotechnology, Healthcare · 200 employees
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company
Funding history
- Funding Round — $75.0M — Sep 2015
Recent signals
- Jan 20, 2026: SEC 8-K (8.01): On January 20, 2026, Corvus Pharmaceuticals, Inc. announced the suspension of its proposed registered underwritten public offering of common stock. This decision was communicated to Jefferies LLC, the underwriter, and relates to a previous Sale Agreement established on August 6, 2024, which permitted the sale of up to $100 million of common stock under a shelf registration statement. Prior to this suspension, no shares had been sold under the agreement, and all $100 million worth of shares remained available for future transactions. The strategic implications of this suspension indicate a potential adjustment in the company's capital raising strategy.
- Dec 04, 2024: Launched Corvus Pharmaceuticals Publishes Preclinical Data on Soquelitinib for Tumor Immunity Modulation
- Feb 06, 2024: Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer
- Sep 25, 2015: Raised $75.0M
See plans & pricing → Track Corvus Pharmaceuticals, Inc.’s funding, hiring, and signals — with verified contacts — on Fundz.